Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ZAHEER ASLAM

Allopathic & Osteopathic Physicians Psychiatry & Neurology Addiction Psychiatry

NPI
1609950468
CMS profile
466115
Location
FORT MYERS, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$84.98

5 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $84.98 5

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
Eisai Inc. $22.21 1
Braeburn Inc. $16.86 1
Almatica Pharma LLC $16.25 1
E.R. Squibb & Sons, L.L.C. $16.21 1
Neurocrine Biosciences, Inc. $13.45 1

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ZAHEER ASLAM

NPI 1609950468 · CMS profile ID 466115

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Addiction Psychiatry

FORT MYERS, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1609950468?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ZAHEER ASLAM, NPI 1609950468, CMS profile ID 466115. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1609950468?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). ZAHEER ASLAM, NPI 1609950468, CMS profile ID 466115. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1609950468?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
ZAHEER ASLAM, NPI 1609950468, CMS profile ID 466115, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1609950468?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

5 matching records · $84.98 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 5 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–5 of 5.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
E.R. Squibb & Sons, L.L.C. $16.2112/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101500336 CMS
Neurocrine Biosciences, Inc. $13.4511/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150878717 CMS
Almatica Pharma LLC $16.2511/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137555502 CMS
Eisai Inc. $22.2106/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110790140 CMS
Braeburn Inc. $16.8602/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125608559 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $37.13 2
PY2020 $65.52 3
PY2021 $42.09 2
PY2023 $1,086.46 10
PY2024 $84.98 5
PY2025 $36.17 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $312,010.46 23
PY2024 Principal investigator $269,570.91 25
PY2023 Principal investigator $238,448.54 19
PY2022 Recipient $9,305.90 2
PY2022 Principal investigator $148,714.11 15
PY2021 Recipient $23,426.10 9
PY2021 Principal investigator $291,910.30 51
PY2020 Principal investigator $331,623.31 81
PY2019 Recipient $171,128.64 8
PY2019 Principal investigator $245,916.89 132

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

81 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Allergan, Inc. $1,080.00 12/31/2020 Non-covered Recipient Entity
GULFCOAST PSYCHIATRIC ASSOCIATES GULFCOAST CLINIC
Randomized, double-blind, placebo- and active-controlled, parallel group, fixed -dose study in pediatric patients, ages 7-17 years. The study will be approximately 10 weeks in duration: 1-week screening/washout period, 8-week double-blind treatment peri No dispute reported 06/30/2026 721318185
Principal investigator 1 Supernus Pharmaceuticals, Inc. $7,033.06 12/18/2020 Non-covered Recipient Entity
GULFCOAST CLINICAL RESEARCH CENTER
AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF SPN-812 IN ADULTS WITH ATTENTION- DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 749583865
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $46.64 12/17/2020 Non-covered Recipient Entity
Gulf Coast Clinical Research
Proof of concept and DRF in MDD No dispute reported 06/30/2026 750752967
Principal investigator 1 Allergan, Inc. $700.00 12/01/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721309991
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $52.42 12/01/2020 Non-covered Recipient Entity
Gulf Coast Clinical Research
Proof of concept and DRF in MDD No dispute reported 06/30/2026 750752961
Principal investigator 1 Supernus Pharmaceuticals, Inc. $1,264.03 11/27/2020 Non-covered Recipient Entity
GULFCOAST CLINICAL RESEARCH CENTER
AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF SPN-812 IN ADULTS WITH ATTENTION- DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 749583693
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $644.32 11/19/2020 Non-covered Recipient Entity
Gulf Coast Clinical Research
Proof of concept and DRF in MDD No dispute reported 06/30/2026 750752965
Principal investigator 1 Supernus Pharmaceuticals, Inc. $2,072.24 11/03/2020 Non-covered Recipient Entity
GULFCOAST CLINICAL RESEARCH CENTER
AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF SPN-812 IN ADULTS WITH ATTENTION- DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 749583571
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $51.25 11/01/2020 Non-covered Recipient Entity
Gulf Coast Clinical Research
Proof of concept and DRF in MDD No dispute reported 06/30/2026 750752945
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $130.00 10/21/2020 Non-covered Recipient Entity
Gulf Coast Clinical Research
Proof of concept and DRF in MDD No dispute reported 06/30/2026 750752939
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $130.00 10/21/2020 Non-covered Recipient Entity
Gulf Coast Clinical Research
Proof of concept and DRF in MDD No dispute reported 06/30/2026 750752943
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $281.60 10/16/2020 Non-covered Recipient Entity
Gulf Coast Clinical Research
Proof of concept and DRF in MDD No dispute reported 06/30/2026 750752955
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $80.00 10/16/2020 Non-covered Recipient Entity
Gulf Coast Clinical Research
Proof of concept and DRF in MDD No dispute reported 06/30/2026 750752959
Principal investigator 1 Sage Therapeutics, Inc. $10,476.70 10/15/2020 Non-covered Recipient Entity
GULFCOAST PSYCHIATRIC ASSOCIATES LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY, TOLERABILITY, AND EFFICACY OF SAGE-217 COMPARED TO PLACEBO IN ADULT SUBJECTS WITH COMORBID MAJOR DEPRESSIVE DISORDER AND INSOMNIA No dispute reported 06/30/2026 749045079
Principal investigator 1 Sage Therapeutics, Inc. $500.50 10/15/2020 Non-covered Recipient Entity
GULFCOAST PSYCHIATRIC ASSOCIATES LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY, TOLERABILITY, AND EFFICACY OF SAGE-217 COMPARED TO PLACEBO IN ADULT SUBJECTS WITH COMORBID MAJOR DEPRESSIVE DISORDER AND INSOMNIA No dispute reported 06/30/2026 749045081
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $51.48 10/01/2020 Non-covered Recipient Entity
Gulf Coast Clinical Research
Proof of concept and DRF in MDD No dispute reported 06/30/2026 750752935
Principal investigator 1 Boehringer Ingelheim International GmbH $83.32 09/25/2020 Non-covered Recipient Entity
Gulf Coast Clinical Research
Proof of concept and DRF in BPD No dispute reported 06/30/2026 749906079
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $992.40 09/24/2020 Non-covered Recipient Entity
Gulf Coast Clinical Research
Proof of concept and DRF in BPD No dispute reported 06/30/2026 751189757
Principal investigator 1 Sage Therapeutics, Inc. $560.00 09/17/2020 Non-covered Recipient Entity
GULFCOAST PSYCHIATRIC ASSOCIATES LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY, TOLERABILITY, AND EFFICACY OF SAGE-217 COMPARED TO PLACEBO IN ADULT SUBJECTS WITH COMORBID MAJOR DEPRESSIVE DISORDER AND INSOMNIA No dispute reported 06/30/2026 749044629
Principal investigator 1 Sage Therapeutics, Inc. $228.80 09/17/2020 Non-covered Recipient Entity
GULFCOAST PSYCHIATRIC ASSOCIATES LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY, TOLERABILITY, AND EFFICACY OF SAGE-217 COMPARED TO PLACEBO IN ADULT SUBJECTS WITH COMORBID MAJOR DEPRESSIVE DISORDER AND INSOMNIA No dispute reported 06/30/2026 749044631
Principal investigator 1 Sage Therapeutics, Inc. $228.80 09/17/2020 Non-covered Recipient Entity
GULFCOAST PSYCHIATRIC ASSOCIATES LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY, TOLERABILITY, AND EFFICACY OF SAGE-217 COMPARED TO PLACEBO IN ADULT SUBJECTS WITH COMORBID MAJOR DEPRESSIVE DISORDER AND INSOMNIA No dispute reported 06/30/2026 749044633
Principal investigator 1 Sage Therapeutics, Inc. $114.40 09/17/2020 Non-covered Recipient Entity
GULFCOAST PSYCHIATRIC ASSOCIATES LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY, TOLERABILITY, AND EFFICACY OF SAGE-217 COMPARED TO PLACEBO IN ADULT SUBJECTS WITH COMORBID MAJOR DEPRESSIVE DISORDER AND INSOMNIA No dispute reported 06/30/2026 749044635
Principal investigator 1 Sage Therapeutics, Inc. $273.00 09/17/2020 Non-covered Recipient Entity
GULFCOAST PSYCHIATRIC ASSOCIATES LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY, TOLERABILITY, AND EFFICACY OF SAGE-217 COMPARED TO PLACEBO IN ADULT SUBJECTS WITH COMORBID MAJOR DEPRESSIVE DISORDER AND INSOMNIA No dispute reported 06/30/2026 749044637
Principal investigator 1 Sage Therapeutics, Inc. $1,228.50 09/17/2020 Non-covered Recipient Entity
GULFCOAST PSYCHIATRIC ASSOCIATES LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY, TOLERABILITY, AND EFFICACY OF SAGE-217 COMPARED TO PLACEBO IN ADULT SUBJECTS WITH COMORBID MAJOR DEPRESSIVE DISORDER AND INSOMNIA No dispute reported 06/30/2026 749044639
Principal investigator 1 Sage Therapeutics, Inc. $1,137.50 09/17/2020 Non-covered Recipient Entity
GULFCOAST PSYCHIATRIC ASSOCIATES LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY, TOLERABILITY, AND EFFICACY OF SAGE-217 COMPARED TO PLACEBO IN ADULT SUBJECTS WITH COMORBID MAJOR DEPRESSIVE DISORDER AND INSOMNIA No dispute reported 06/30/2026 749044641
Principal investigator 1 Sage Therapeutics, Inc. $253.50 09/17/2020 Non-covered Recipient Entity
GULFCOAST PSYCHIATRIC ASSOCIATES LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY, TOLERABILITY, AND EFFICACY OF SAGE-217 COMPARED TO PLACEBO IN ADULT SUBJECTS WITH COMORBID MAJOR DEPRESSIVE DISORDER AND INSOMNIA No dispute reported 06/30/2026 749044643
Principal investigator 1 Sage Therapeutics, Inc. $500.00 09/17/2020 Non-covered Recipient Entity
GULFCOAST PSYCHIATRIC ASSOCIATES LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY, TOLERABILITY, AND EFFICACY OF SAGE-217 COMPARED TO PLACEBO IN ADULT SUBJECTS WITH COMORBID MAJOR DEPRESSIVE DISORDER AND INSOMNIA No dispute reported 06/30/2026 749044645
Principal investigator 1 Sage Therapeutics, Inc. $160.00 09/17/2020 Non-covered Recipient Entity
GULFCOAST PSYCHIATRIC ASSOCIATES LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY, TOLERABILITY, AND EFFICACY OF SAGE-217 COMPARED TO PLACEBO IN ADULT SUBJECTS WITH COMORBID MAJOR DEPRESSIVE DISORDER AND INSOMNIA No dispute reported 06/30/2026 749044647
Principal investigator 1 Sage Therapeutics, Inc. $84.50 09/17/2020 Non-covered Recipient Entity
GULFCOAST PSYCHIATRIC ASSOCIATES LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY, TOLERABILITY, AND EFFICACY OF SAGE-217 COMPARED TO PLACEBO IN ADULT SUBJECTS WITH COMORBID MAJOR DEPRESSIVE DISORDER AND INSOMNIA No dispute reported 06/30/2026 749044649
Principal investigator 1 Sage Therapeutics, Inc. $160.00 09/17/2020 Non-covered Recipient Entity
GULFCOAST PSYCHIATRIC ASSOCIATES LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY, TOLERABILITY, AND EFFICACY OF SAGE-217 COMPARED TO PLACEBO IN ADULT SUBJECTS WITH COMORBID MAJOR DEPRESSIVE DISORDER AND INSOMNIA No dispute reported 06/30/2026 749044651
Principal investigator 1 Sage Therapeutics, Inc. $195.00 09/17/2020 Non-covered Recipient Entity
GULFCOAST PSYCHIATRIC ASSOCIATES LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY, TOLERABILITY, AND EFFICACY OF SAGE-217 COMPARED TO PLACEBO IN ADULT SUBJECTS WITH COMORBID MAJOR DEPRESSIVE DISORDER AND INSOMNIA No dispute reported 06/30/2026 749044653
Principal investigator 1 Sage Therapeutics, Inc. $45.50 09/17/2020 Non-covered Recipient Entity
GULFCOAST PSYCHIATRIC ASSOCIATES LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY, TOLERABILITY, AND EFFICACY OF SAGE-217 COMPARED TO PLACEBO IN ADULT SUBJECTS WITH COMORBID MAJOR DEPRESSIVE DISORDER AND INSOMNIA No dispute reported 06/30/2026 749044655
Principal investigator 1 Sage Therapeutics, Inc. $84.50 09/17/2020 Non-covered Recipient Entity
GULFCOAST PSYCHIATRIC ASSOCIATES LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY, TOLERABILITY, AND EFFICACY OF SAGE-217 COMPARED TO PLACEBO IN ADULT SUBJECTS WITH COMORBID MAJOR DEPRESSIVE DISORDER AND INSOMNIA No dispute reported 06/30/2026 749044657
Principal investigator 1 Sage Therapeutics, Inc. $155.00 09/17/2020 Non-covered Recipient Entity
GULFCOAST PSYCHIATRIC ASSOCIATES LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY, TOLERABILITY, AND EFFICACY OF SAGE-217 COMPARED TO PLACEBO IN ADULT SUBJECTS WITH COMORBID MAJOR DEPRESSIVE DISORDER AND INSOMNIA No dispute reported 06/30/2026 749044659
Principal investigator 1 Sage Therapeutics, Inc. $214.50 09/17/2020 Non-covered Recipient Entity
GULFCOAST PSYCHIATRIC ASSOCIATES LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY, TOLERABILITY, AND EFFICACY OF SAGE-217 COMPARED TO PLACEBO IN ADULT SUBJECTS WITH COMORBID MAJOR DEPRESSIVE DISORDER AND INSOMNIA No dispute reported 06/30/2026 749044661
Principal investigator 1 Sage Therapeutics, Inc. $45.50 09/17/2020 Non-covered Recipient Entity
GULFCOAST PSYCHIATRIC ASSOCIATES LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY, TOLERABILITY, AND EFFICACY OF SAGE-217 COMPARED TO PLACEBO IN ADULT SUBJECTS WITH COMORBID MAJOR DEPRESSIVE DISORDER AND INSOMNIA No dispute reported 06/30/2026 749044663
Principal investigator 1 Sage Therapeutics, Inc. $195.00 09/17/2020 Non-covered Recipient Entity
GULFCOAST PSYCHIATRIC ASSOCIATES LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY, TOLERABILITY, AND EFFICACY OF SAGE-217 COMPARED TO PLACEBO IN ADULT SUBJECTS WITH COMORBID MAJOR DEPRESSIVE DISORDER AND INSOMNIA No dispute reported 06/30/2026 749044665
Principal investigator 1 Sage Therapeutics, Inc. $45.50 09/17/2020 Non-covered Recipient Entity
GULFCOAST PSYCHIATRIC ASSOCIATES LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY, TOLERABILITY, AND EFFICACY OF SAGE-217 COMPARED TO PLACEBO IN ADULT SUBJECTS WITH COMORBID MAJOR DEPRESSIVE DISORDER AND INSOMNIA No dispute reported 06/30/2026 749044667
Principal investigator 1 Sage Therapeutics, Inc. $45.50 09/17/2020 Non-covered Recipient Entity
GULFCOAST PSYCHIATRIC ASSOCIATES LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY, TOLERABILITY, AND EFFICACY OF SAGE-217 COMPARED TO PLACEBO IN ADULT SUBJECTS WITH COMORBID MAJOR DEPRESSIVE DISORDER AND INSOMNIA No dispute reported 06/30/2026 749044669
Principal investigator 1 Sage Therapeutics, Inc. $175.00 09/17/2020 Non-covered Recipient Entity
GULFCOAST PSYCHIATRIC ASSOCIATES LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY, TOLERABILITY, AND EFFICACY OF SAGE-217 COMPARED TO PLACEBO IN ADULT SUBJECTS WITH COMORBID MAJOR DEPRESSIVE DISORDER AND INSOMNIA No dispute reported 06/30/2026 749044671
Principal investigator 1 Sage Therapeutics, Inc. $225.00 09/17/2020 Non-covered Recipient Entity
GULFCOAST PSYCHIATRIC ASSOCIATES LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY, TOLERABILITY, AND EFFICACY OF SAGE-217 COMPARED TO PLACEBO IN ADULT SUBJECTS WITH COMORBID MAJOR DEPRESSIVE DISORDER AND INSOMNIA No dispute reported 06/30/2026 749044673
Principal investigator 1 Sage Therapeutics, Inc. $546.00 09/17/2020 Non-covered Recipient Entity
GULFCOAST PSYCHIATRIC ASSOCIATES LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY, TOLERABILITY, AND EFFICACY OF SAGE-217 COMPARED TO PLACEBO IN ADULT SUBJECTS WITH COMORBID MAJOR DEPRESSIVE DISORDER AND INSOMNIA No dispute reported 06/30/2026 749044675
Principal investigator 1 Sage Therapeutics, Inc. $227.50 09/17/2020 Non-covered Recipient Entity
GULFCOAST PSYCHIATRIC ASSOCIATES LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY, TOLERABILITY, AND EFFICACY OF SAGE-217 COMPARED TO PLACEBO IN ADULT SUBJECTS WITH COMORBID MAJOR DEPRESSIVE DISORDER AND INSOMNIA No dispute reported 06/30/2026 749044677
Principal investigator 1 Sage Therapeutics, Inc. $1,500.00 09/17/2020 Non-covered Recipient Entity
GULFCOAST PSYCHIATRIC ASSOCIATES LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY, TOLERABILITY, AND EFFICACY OF SAGE-217 COMPARED TO PLACEBO IN ADULT SUBJECTS WITH COMORBID MAJOR DEPRESSIVE DISORDER AND INSOMNIA No dispute reported 06/30/2026 749044679
Principal investigator 1 Sage Therapeutics, Inc. $400.00 09/17/2020 Non-covered Recipient Entity
GULFCOAST PSYCHIATRIC ASSOCIATES LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY, TOLERABILITY, AND EFFICACY OF SAGE-217 COMPARED TO PLACEBO IN ADULT SUBJECTS WITH COMORBID MAJOR DEPRESSIVE DISORDER AND INSOMNIA No dispute reported 06/30/2026 749044681
Principal investigator 1 Sage Therapeutics, Inc. $500.00 09/17/2020 Non-covered Recipient Entity
GULFCOAST PSYCHIATRIC ASSOCIATES LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY, TOLERABILITY, AND EFFICACY OF SAGE-217 COMPARED TO PLACEBO IN ADULT SUBJECTS WITH COMORBID MAJOR DEPRESSIVE DISORDER AND INSOMNIA No dispute reported 06/30/2026 749044683
Principal investigator 1 Sage Therapeutics, Inc. $300.00 09/17/2020 Non-covered Recipient Entity
GULFCOAST PSYCHIATRIC ASSOCIATES LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY, TOLERABILITY, AND EFFICACY OF SAGE-217 COMPARED TO PLACEBO IN ADULT SUBJECTS WITH COMORBID MAJOR DEPRESSIVE DISORDER AND INSOMNIA No dispute reported 06/30/2026 749044685
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $85.45 09/14/2020 Non-covered Recipient Entity
Gulf Coast Clinical Research
Proof of concept and DRF in MDD No dispute reported 06/30/2026 750752949
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $26.58 09/14/2020 Non-covered Recipient Entity
Gulf Coast Clinical Research
Proof of concept and DRF in MDD No dispute reported 06/30/2026 750752952
Principal investigator 1 Sage Therapeutics, Inc. $1,500.00 09/10/2020 Non-covered Recipient Entity
GULFCOAST PSYCHIATRIC ASSOCIATES LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY, TOLERABILITY, AND EFFICACY OF SAGE-217 COMPARED TO PLACEBO IN ADULT SUBJECTS WITH COMORBID MAJOR DEPRESSIVE DISORDER AND INSOMNIA No dispute reported 06/30/2026 749044607
Principal investigator 1 Allergan, Inc. $8,500.00 08/13/2020 Non-covered Recipient Entity
GULFCOAST PSYCHIATRIC ASSOCIATES GULFCOAST CLINIC
Mono Ph 3 #2 DBPC No dispute reported 06/30/2026 721290199
Principal investigator 1 Supernus Pharmaceuticals, Inc. $2,539.36 08/03/2020 Non-covered Recipient Entity
GULFCOAST CLINICAL RESEARCH CENTER
AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF SPN-812 IN ADULTS WITH ATTENTION- DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 749583095
Principal investigator 1 Supernus Pharmaceuticals, Inc. $1,401.36 07/01/2020 Non-covered Recipient Entity
GULFCOAST CLINICAL RESEARCH CENTER
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) No dispute reported 06/30/2026 749582811
Principal investigator 1 Supernus Pharmaceuticals, Inc. $5,132.62 07/01/2020 Non-covered Recipient Entity
GULFCOAST CLINICAL RESEARCH CENTER
AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF SPN-812 IN ADULTS WITH ATTENTION- DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 749582863
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $825.00 06/10/2020 Non-covered Recipient Entity
CLINTRAX GLOBAL INC
BIOANALYSIS OF JZP-110 (SOLRIAMTETOL) IN HUMAN PLASMA BY LC-MS/MS IN SUPPORT OF PROTOCOL JZP188-301 No dispute reported 06/30/2026 744485231
Principal investigator 1 Supernus Pharmaceuticals, Inc. $5,095.64 06/01/2020 Non-covered Recipient Entity
GULFCOAST CLINICAL RESEARCH CENTER
AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF SPN-812 IN ADULTS WITH ATTENTION- DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 749582673
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $22,975.00 05/28/2020 Non-covered Recipient Entity
GULFCOAST PSYCHIATRIC ASSOCIATES LLC
BREXPIPRAZOLE AS COMBINATION THERAPY WITH SERTRALINE IN THE TREATMENT OF ADULTS WITH POST-TRAUMATIC STRESS DISORDER No dispute reported 06/30/2026 748804969
Principal investigator 1 Supernus Pharmaceuticals, Inc. $1,454.64 05/08/2020 Non-covered Recipient Entity
GULFCOAST CLINICAL RESEARCH CENTER
AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF SPN-812 IN ADULTS WITH ATTENTION- DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 749582479
Principal investigator 1 Supernus Pharmaceuticals, Inc. $31,962.73 05/08/2020 Non-covered Recipient Entity
GULFCOAST CLINICAL RESEARCH CENTER
AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF SPN-812 IN ADULTS WITH ATTENTION- DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 749582481
Principal investigator 1 Sage Therapeutics, Inc. $29,348.31 05/07/2020 Non-covered Recipient Entity
GULFCOAST PSYCHIATRIC ASSOCIATES LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY, TOLERABILITY, AND EFFICACY OF SAGE-217 COMPARED TO PLACEBO IN ADULT SUBJECTS WITH COMORBID MAJOR DEPRESSIVE DISORDER AND INSOMNIA No dispute reported 06/30/2026 749042833
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $21,318.00 04/23/2020 Non-covered Recipient Entity
GULFCOAST PSYCHIATRIC ASSOCIATES LLC
A MULTICENTER, RANDOMIZED, FLEXIBLE-DOSE, DOUBLE BLIND TRIAL OF BREXPIPRAZOLE VERSUS PLACEBO FOR THE TREATMENT OF ADULTS WITH BORDERLINE PERSONALITY DISORDER No dispute reported 06/30/2026 748804605
Principal investigator 1 Supernus Pharmaceuticals, Inc. $51,324.99 04/02/2020 Non-covered Recipient Entity
GULFCOAST CLINICAL RESEARCH CENTER
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) No dispute reported 06/30/2026 749582235
Principal investigator 1 Supernus Pharmaceuticals, Inc. $6,500.00 03/13/2020 Non-covered Recipient Entity
GULFCOAST CLINICAL RESEARCH CENTER
AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF SPN-812 IN ADULTS WITH ATTENTION- DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 749582121
Principal investigator 1 Allergan, Inc. $327.00 03/12/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
AN OPEN LABEL, LONG TERM-EXTENDED ACCESS PROTOCOL FOR RAPASTINEL AS ADJUNCTIVE OR MONOTHERAPY TREATMENT IN PATIENTS WITH MAYOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721263269
Principal investigator 1 Sage Therapeutics, Inc. $5,000.00 03/12/2020 Non-covered Recipient Entity
GULFCOAST PSYCHIATRIC ASSOCIATES LLC
217-MDD-304 No dispute reported 06/30/2026 749042187
Principal investigator 1 Sage Therapeutics, Inc. $750.00 03/12/2020 Non-covered Recipient Entity
GULFCOAST PSYCHIATRIC ASSOCIATES LLC
217-MDD-304 No dispute reported 06/30/2026 749042189
Principal investigator 1 Sage Therapeutics, Inc. $188.92 03/12/2020 Non-covered Recipient Entity
GULFCOAST PSYCHIATRIC ASSOCIATES LLC
217-MDD-304 No dispute reported 06/30/2026 749042191
Principal investigator 1 Sage Therapeutics, Inc. $40,645.21 03/12/2020 Non-covered Recipient Entity
GULFCOAST PSYCHIATRIC ASSOCIATES LLC
217-MDD-304 No dispute reported 06/30/2026 749042193
Principal investigator 1 Sage Therapeutics, Inc. $1,833.39 03/12/2020 Non-covered Recipient Entity
GULFCOAST PSYCHIATRIC ASSOCIATES LLC
217-MDD-304 No dispute reported 06/30/2026 749042195
Principal investigator 1 Sage Therapeutics, Inc. $12,399.40 03/12/2020 Non-covered Recipient Entity
GULFCOAST PSYCHIATRIC ASSOCIATES LLC
217-MDD-304 No dispute reported 06/30/2026 749042197
Principal investigator 1 Supernus Pharmaceuticals, Inc. $2,482.92 03/02/2020 Non-covered Recipient Entity
GULFCOAST CLINICAL RESEARCH CENTER
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) No dispute reported 06/30/2026 749581987
Principal investigator 1 Allergan, Inc. $3,000.00 03/01/2020 Non-covered Recipient Entity
GULFCOAST PSYCHIATRIC ASSOCIATES GULFCOAST CLINIC
A Randomized, Double-blind, Placebo-controlled, Multicenter, Efficacy and Safety Study of Rapastinel for Rapid Treatment of Symptoms of Depression and Suicidality in Adult Patients with Major Depressive Disorder No dispute reported 06/30/2026 721261273
Principal investigator 1 Supernus Pharmaceuticals, Inc. $2,000.00 02/21/2020 Non-covered Recipient Entity
GULFCOAST CLINICAL RESEARCH CENTER
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) No dispute reported 06/30/2026 749581945
Principal investigator 1 Allergan, Inc. $250.00 01/28/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A DOUBLE BLIND, PLACEBO- AND ACTIVE CONTROLLED EVALUATION OF THE SAFETY AND EFFICACY OF LEVOMILNACIPRAN ER IN ADOLESCENT PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721251723
Principal investigator 1 Allergan, Inc. $385.00 01/28/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY OF RAPASTINEL AS ADJUNCTIVE THERAPY IN THE PREVENTION OF RELAPSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721253263
Principal investigator 1 Sage Therapeutics, Inc. $33,851.61 01/23/2020 Non-covered Recipient Entity
GULFCOAST PSYCHIATRIC ASSOCIATES LLC
217-MDD-304 No dispute reported 06/30/2026 749041343
Principal investigator 1 Alkermes, Inc. $3,000.00 01/09/2020 Non-covered Recipient Entity
GULFCOAT CLINICAL RESEARCH CENTER
A Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder No dispute reported 06/30/2026 724170057
Principal investigator 1 Alkermes, Inc. $10.10 01/01/2020 Non-covered Recipient Entity
GULFCOAT CLINICAL RESEARCH CENTER
A Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder No dispute reported 06/30/2026 724170043
Principal investigator 1 Alkermes, Inc. $10.10 01/01/2020 Non-covered Recipient Entity
GULFCOAT CLINICAL RESEARCH CENTER
A Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder No dispute reported 06/30/2026 724170047
Principal investigator 1 Alkermes, Inc. $0.76 01/01/2020 Non-covered Recipient Entity
GULFCOAT CLINICAL RESEARCH CENTER
A Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder No dispute reported 06/30/2026 724170051
Principal investigator 1 Alkermes, Inc. $0.76 01/01/2020 Non-covered Recipient Entity
GULFCOAT CLINICAL RESEARCH CENTER
A Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder No dispute reported 06/30/2026 724170053